{"id":"NCT02175277","sponsor":"Amgen","briefTitle":"Darbepoetin Alfa MDS Companion Protocol","officialTitle":"Single Arm, Companion Study to Myelodysplastic Syndrome (MDS) 20090160 Using Darbepoetin Alfa for the Treatment of Anaemic Subjects With Myelodysplastic Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06-12","primaryCompletion":"2017-03-20","completion":"2017-03-20","firstPosted":"2014-06-26","resultsPosted":"2018-10-11","lastUpdate":"2018-11-14"},"enrollment":9,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Myelodysplastic Syndrome (MDS)"],"interventions":[{"type":"DRUG","name":"Darbepoetin Alfa","otherNames":["AranespÂ®"]}],"arms":[{"label":"Darbepoetin Alfa","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study was to provide required access of investigational product (darbepoetin alfa) beyond the end of the active treatment period (EOATP) of the darbepoetin alfa MDS 20090160 (NCT01362140) study for patients who had continued demonstration of benefit from darbepoetin alfa treatment and to describe the safety of longer-term use in this patient population.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events","timeFrame":"From first dose of darbepoetin alfa to 30 days after last dose; the maximum treatment duration was 73 weeks.","effectByArm":[{"arm":"Darbepoetin Alfa","deltaMin":9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":4,"countries":["Belgium"]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":9},"commonTop":["Fatigue","Dyspnoea exertional","Abdominal discomfort","Cough","Oropharyngeal pain"]}}